Intech Biopharm Ltd Cash Flow Conversion Efficiency

Latest as of March 2026: -0.085x

Intech Biopharm Ltd cash flow conversion efficiency. Based on the latest financial reports, Intech Biopharm Ltd (6461) has a cash flow conversion efficiency ratio of -0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-84.50 Million ≈ $-2.66 Million USD) by net assets (NT$991.64 Million ≈ $31.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Intech Biopharm Ltd (2017–2025)

Cash flow conversion efficiency of Intech Biopharm Ltd from 2017 to 2025. This chart illustrates how Intech Biopharm Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6461 share price today for real-time trading data and today's change.

Intech Biopharm Ltd Cash Flow Conversion Ratio Explained

Intech Biopharm Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Intech Biopharm Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Intech Biopharm Ltd ranked by their cash flow conversion efficiency. Also see market value of Intech Biopharm Ltd for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Anixa Biosciences Inc NASDAQ:ANIX	-0.134x
Pantages Capital Acquisition Corporation. NASDAQ:PGAC	-0.003x
Solborn Inc KQ:035610	0.018x
Emvision Medical Devices Ltd AU:EMV	-0.301x
Hsin Ba Ba Corp TW:9906	-0.185x
Softstar Entertainment TWO:6111	-0.024x
Spheria Emerging Companies Ltd AU:SEC	0.046x
AKA Brands Holding Corp NYSE:AKA	-0.041x

Annual Cash Flow Conversion Efficiency for Intech Biopharm Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Intech Biopharm Ltd from 2017 to 2025. Review 6461 free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$1.10 Billion ≈ $34.69 Million	NT$-361.13 Million ≈ $-11.38 Million	-0.328x	+0.79%
2024-12-31	NT$814.28 Million ≈ $25.65 Million	NT$-269.22 Million ≈ $-8.48 Million	-0.331x	-89.15%
2023-12-31	NT$1.17 Billion ≈ $36.79 Million	NT$-204.13 Million ≈ $-6.43 Million	-0.175x	+5.28%
2022-12-31	NT$1.03 Billion ≈ $32.50 Million	NT$-190.39 Million ≈ $-6.00 Million	-0.185x	-23.05%
2021-12-31	NT$1.34 Billion ≈ $42.14 Million	NT$-200.61 Million ≈ $-6.32 Million	-0.150x	-19.06%
2020-12-31	NT$1.33 Billion ≈ $41.86 Million	NT$-167.38 Million ≈ $-5.27 Million	-0.126x	-4.52%
2019-12-31	NT$1.57 Billion ≈ $49.43 Million	NT$-189.09 Million ≈ $-5.96 Million	-0.121x	+22.84%
2018-12-31	NT$1.49 Billion ≈ $46.88 Million	NT$-232.43 Million ≈ $-7.32 Million	-0.156x	-45.69%
2017-12-31	NT$1.36 Billion ≈ $42.70 Million	NT$-145.29 Million ≈ $-4.58 Million	-0.107x	--

About Intech Biopharm Ltd

TWO:6461 Taiwan Biotechnology

Market Cap

$95.93 Million

NT$3.04 Billion TWD

Market Cap Rank

#19182 Global

#1080 in Taiwan

Share Price

NT$27.60

Change (1 day)

+1.47%

52-Week Range

NT$14.40 - NT$29.20

All Time High

NT$57.64